The American College of Rheumatology has always stood for affordable and accessible healthcare coverage for the 54 million Americans living with rheumatic diseases. We are concerned the discussion draft of the Better Care Reconciliation Act introduced by Senate leadership this morning falls short of that goal. We stand ready to work with the Senate leadership…
Search results for: hip OA
Medical Education Evolves
Medical education programs are changing. Tiffany Lin, MD, discusses a curriculum designed around patient-centered case studies and why a new accreditation process is a welcome change…
News Updates for Diclofenac Sodium, Denosumab & Sarilumab
In drug news, a generic 2% diclofenac sodium solution is now available, denosumab is promising to treat osteoporosis, and the FDA has approved sarilumab to treat adults with RA…
The Walk from the Waiting Room
For a rheumatology practice, rooming time can be leveraged to improve efficiency and patient care. Christie Bartels, MD, MS, and colleagues have studied this time frame and developed data-based tips and tools to decrease variation among staff and streamline practices…
Why I Advocate for Rheumatology: Teaching the Basics
If you speak to any advocate for rheumatology, each of us has an “Aha! moment,” when we learned the importance of advocacy. My own came a dozen years ago. I was meeting with a legislative aide to a local congressman who was a senior member of the committee overseeing Medicare. He introduced himself as the…
The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology
Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…
RISE Summit Establishes Priorities, Direction for Registry
On Feb. 16, ACR leaders, insurers, pharmaceutical representatives, patients, patient advocacy representatives and more met in Scottsdale, Ariz. They came together for the first annual RISE Summit, aimed at setting strategic priorities and goals for the Rheumatology Informatics System for Effectiveness (RISE) Registry, the qualified clinical data registry developed by the ACR. The Rise of…
ACR Works for Global Access to Meeting
Thousands of attendees travel to the ACR/ARHP Annual Meeting from outside the U.S. to learn, network and exchange ideas. From Nov. 3–8 in San Diego, speakers from more than 30 different countries are scheduled to participate. The ACR is taking action to maintain diverse attendance in a challenging climate for international travel. New traveler vetting and…
The ACR Is Exploring a Rheumatology-Specific APM
In response to the required changes in reimbursement from fee for service to value-based payment under the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015, the ACR is exploring development of a rheumatology-specific alternative payment model (APM) for rheumatologists and practices, which would provide an additional option for payment other than the Merit-Based Incentive…
More Effective Antifibrotic Therapies for Systemic Sclerosis in Development; Adverse Events A Concern
Systemic sclerosis (SSc) is a rare disease affecting about 49,000 U.S. adults, and it is strongly associated with high levels of morbidity and mortality.1 Of the few available antifibrotic therapies, none is targeted for SSc. However, reason for optimism exists for antifibrotic treatments in early development and clinical trials, says Jörg H.W. Distler, MD, Heisenberg Professor…
- « Previous Page
- 1
- …
- 196
- 197
- 198
- 199
- 200
- …
- 331
- Next Page »